How blood-testing startups are pitching themselves after the Theranos scandal

Startup Genalyte Inc. wants to revolutionize the way blood testing is done.

If its vision pans out, the privately held company’s proprietary technology will be able to run dozens of blood tests using a tiny amount of blood, and in a way that’s quicker and more accessible than in the traditional lab setting.

Perhaps that’s a premise that sounds familiar — and not in a comforting way. Another blood-testing startup, Theranos, the subject of a thorough Wall Street Journal exposé, was effectively labeled a “massive” financial fraud by the Securities and Exchange Commission. Last week, federal prosecutors filed criminal charges against two former top Theranos executives.

>>> Original Source <<<